구조모아 (StructureMoa)항암 chemical structure spider web
방문JohnsonJohnsonLegend Biotech
분석
큐레이션 브리핑
경쟁 포지션: Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
기전. Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA
Relapsed or refractory multiple myeloma
US, EU, JP
Approved
carvykti · ciltacabtagene autoleucel · Carvykti · cilta-cel · JNJ-68284528 · LCAR-B38M
2026-09-10
Data Confidence · High
Development Signal · Established
Autologous CAR-T cell therapy
Lentiviral
Two BCMA-binding VHH (camelid single-domain) sequences in tandem, 4-1BB costimulation, CD3ζ signaling
Patient apheresis, ex vivo transduction and expansion, single infusion
Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs.
구조화 데이터
Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs.
BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche.
Lentiviral
BCMA · BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence.
CRS, ICANS, delayed movement and neurocognitive toxicity, prolonged cytopenia
Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
R/R multiple myeloma after ≥1 prior line including a PI and lenalidomide
2L+ (originally 4L+)
Single IV infusion after lymphodepletion
One-time
ORR ~97% in CARTITUDE-1
CRS, ICANS, delayed movement and neurocognitive toxicity, prolonged cytopenia
Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion.
CAR-T expansion peaks around days 10–14 with IL-6 and IFN-γ elevation.
Perforin/granzyme-mediated lysis of BCMA+ plasma cells.
BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence.
BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche.
구조화 데이터
Human
Cellular expansion kinetics rather than classical half-life
Peak CAR transgene level, MRD negativity, soluble BCMA decline
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (4L+ myeloma)
APPROVAL · 2022년 2월
Second-line expansion on CARTITUDE-4
APPROVAL · 2024년 4월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
JohnsonJohnsonLegend Biotech
분석
큐레이션 브리핑
경쟁 포지션: Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
기전. Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
BCMA
Relapsed or refractory multiple myeloma
US, EU, JP
Approved
carvykti · ciltacabtagene autoleucel · Carvykti · cilta-cel · JNJ-68284528 · LCAR-B38M
2026-09-10
Data Confidence · High
Development Signal · Established
Autologous CAR-T cell therapy
Lentiviral
Two BCMA-binding VHH (camelid single-domain) sequences in tandem, 4-1BB costimulation, CD3ζ signaling
Patient apheresis, ex vivo transduction and expansion, single infusion
Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs.
구조화 데이터
Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs.
BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche.
Lentiviral
BCMA · BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence.
CRS, ICANS, delayed movement and neurocognitive toxicity, prolonged cytopenia
Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
R/R multiple myeloma after ≥1 prior line including a PI and lenalidomide
2L+ (originally 4L+)
Single IV infusion after lymphodepletion
One-time
ORR ~97% in CARTITUDE-1
CRS, ICANS, delayed movement and neurocognitive toxicity, prolonged cytopenia
Best-in-class efficacy in BCMA CAR-T, ahead of Abecma on depth of response.
Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion.
CAR-T expansion peaks around days 10–14 with IL-6 and IFN-γ elevation.
Perforin/granzyme-mediated lysis of BCMA+ plasma cells.
BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence.
BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche.
구조화 데이터
Human
Cellular expansion kinetics rather than classical half-life
Peak CAR transgene level, MRD negativity, soluble BCMA decline
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (4L+ myeloma)
APPROVAL · 2022년 2월
Second-line expansion on CARTITUDE-4
APPROVAL · 2024년 4월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.